 |
|
Striatal Metabolic Rate and Clinical Response to Neuroleptics in Schizophrenia
Monte S. Buchsbaum, MD;
Steven G. Potkin, MD;
Benjamin V. Siegel, Jr, MD;
James Lohr, MD;
Mark Katz, MD;
Louis A. Gottschalk, MD;
Bala Gulasekaram, MD;
John F. Marshall, PhD;
Stephen Lottenberg, MD;
Chuck Ying Teng;
Lennart Abel;
Lawrence Plon, PharmD;
William E. Bunney, Jr, MD
Arch Gen Psychiatry. 1992;49(12):966-974.
Abstract
• A low metabolic rate in the caudate nucleus and putamen in schizophrenic patients while they were not receiving medication was found to predict a favorable clinical response to haloperidol. Twenty-five patients (21 men and four women) entered a double-blind crossover trial of haloperidol and placebo; to our knowledge, this is the first such trial with positron emission tomography to be reported. Patients received either placebo or medication for the first 5 weeks, and they received the other treatment for the second 5 weeks. Positron emission tomographic scans were obtained at weeks 5 and 10. Patients with low relative metabolic rates in the caudate nucleus and putamen while they were receiving placebo were more likely to show decreases in their Brief Psychiatric Rating Scale scores with haloperidol treatment than individuals with normal or high metabolic rates. Among responders, haloperidol treatment had a "normalizing" effect on metabolic activity in the striatum, with the metabolic rate while they were receiving haloperidol being higher than that while they were receiving placebo. Nonresponders were more likely to show a worsening of hypofrontality while they were receiving medication and an absence of change in the striatum.
Author Affiliations
From the Departments of Psychiatry and Human Behavior (Drs Buchsbaum, Potkin, Siegel, Katz, Gottschalk, Lottenberg, and Bunney and Messrs Teng and Abel) and Psychobiology (Dr Marshall) and the University of California Irvine Medical Center (Dr Plon), University of California, Irvine; the Department of Psychiatry, University of California at San Diego, La Jolla (Dr Lohr); and the Metropolitan State Hospital, Norwalk, Calif (Dr Gulasekaram). Dr Buchsbaum is now with the Department of Psychiatry, Mount Sinai School of Medicine, New York, NY.
Footnotes
Accepted for publication January 30, 1992.
Reprint requests to Department of Psychiatry, Mount Sinai School of Medicine, Box 1230, 1 Gustave L. Levy PI, New York, NY 10029 (Dr Buchsbaum).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Review: The biological basis of antipsychotic response in schizophrenia
Stone et al.
J Psychopharmacol 2010;24:953-964.
ABSTRACT
Functional brain mapping of psychopathology
Honey et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:432-439.
ABSTRACT
| FULL TEXT
Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change
Ngan et al.
J. Neurol. Neurosurg. Psychiatry 2002;72:106-110.
ABSTRACT
| FULL TEXT
Topical Review: Functional Brain Imaging in Neuropsychiatric Disorders of Childhood
O'Tuama et al.
J Child Neurol 1999;14:207-221.
ABSTRACT
Dorsal Striatal Size, Shape, and Metabolic Rate in Never-Medicated and Previously Medicated Schizophrenics Performing a Verbal Learning Task
Shihabuddin et al.
Arch Gen Psychiatry 1998;55:235-243.
ABSTRACT
| FULL TEXT
The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Patients With Schizophrenia During a Continuous Performance Task
Cohen et al.
Arch Gen Psychiatry 1997;54:481-486.
ABSTRACT
Clozapine Treatment of Schizophrenia
Pickar and Hsiao
JAMA 1995;274:981-983.
ABSTRACT
Resting Cerebral Glucose Metabolism in First-Episode and Previously Treated Patients With Schizophrenia Relates to Clinical Features
Gur et al.
Arch Gen Psychiatry 1995;52:657-667.
ABSTRACT
|
